Inflammation and Coronary Artery Disease: Role of AT1-Receptor Antagonism

Exclusion Criteria

• •1. Acute coronary syndromes.
• •2. Acute or chronic heart failure (left ventricular ejection fraction \< 45 %).
• •3. Symptomatic valvular heart disease.
• •4. Inflammatory diseases (e.g., acute infection, rheumatic diseases, collagenosis).
• •5. Pre-menopausal women (last menstruation \< 1 year prior to start of run-in period) who:
• •* Are not surgically sterile.
• •* Are nursing.
• •* Are of child-bearing potential and are NOT practicing acceptable means of birth control, do NOT plan to continue using this method throughout the study and do NOT agree to submit to periodic pregnancy testing during participation in studies of \> 3-months duration. Acceptable methods of birth control include oral, implantable or injectable contraceptives.
• •6. Known or suspected secondary hypertension.
• •7. Mean sitting SBP \> 160 mm Hg or mean sitting DBP \> 95 mm Hg during any visit.
• •8. Hepatic and/or renal dysfunction as defined by the following laboratory parameters:
• •* SGPT(ALT) or SGOT(AST) \> than 2 times the upper limit of normal range .
• •* Serum creatinine \> 2.3 mg/dL.
• •9. Bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, patients post-renal transplant or with only one kidney.
• •10. Clinically relevant hypokalaemia or hyperkalaemia.
• •11. Uncorrected volume depletion.
• •12. Uncorrected sodium depletion.
• •13. Primary aldosteronism.
• •14. Hereditary fructose intolerance.
• •15. Biliary obstructive disorders.
• •16. Patients who have previously experienced symptoms characteristic of angioedema during treatment with ACE inhibitors or angiotensin II receptor antagonists.
• •17. History of drug or alcohol dependency within 6 months.
• •18. Chronic administration of any medications known to affect blood pressure, except medication allowed by the protocol (cf. 4.2.1).
• •19. Current participation in another trial, or participation in a trial within a period of one month.
• •20. Known hypersensitivity to any component of the formulation.
• •21. Has no contra-indication to a placebo run-in period (e.g., recent stroke or MI).
• •22. Any other clinical condition which, in the opinion of the principal investigator, would not allow safe completion of the protocol and safe administration of telmisartan.